Insider Trading Alert - LHCG, Y And ZIOP Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, June 5, 2015, 80 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $368.50 to $15,580,000.00.

Highlighted Stocks Traded by Insiders:

LHC Group (LHCG) - FREE Research Report

Nixon Ronald T, who is Director at LHC Group, sold 4,000 shares at $36.25 on June 5, 2015. Following this transaction, the Director owned 45,400 shares meaning that the stake was reduced by 8.1% with the 4,000-share transaction.

The shares most recently traded at $36.23, down $0.02, or 0.06% since the insider transaction. Historical insider transactions for LHC Group go as follows:

  • 4-Week # shares sold: 15,070
  • 12-Week # shares sold: 15,070
  • 24-Week # shares sold: 15,070

The average volume for LHC Group has been 70,600 shares per day over the past 30 days. LHC Group has a market cap of $651.0 million and is part of the health care sector and health services industry. Shares are up 16.2% year-to-date as of the close of trading on Friday.

LHC Group, Inc., together with its subsidiaries, provides post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through three segments: Home-Based Services, Hospice Services, and Facility-Based Services. The company has a P/E ratio of 25.7. Currently, there are 3 analysts who rate LHC Group a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LHCG - FREE

TheStreet Quant Ratings rates LHC Group as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full LHC Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alleghany (Y) - FREE Research Report

Lavin William K, who is Director at Alleghany, sold 250 shares at $475.75 on June 5, 2015. Following this transaction, the Director owned 2,352 shares meaning that the stake was reduced by 9.61% with the 250-share transaction.

The shares most recently traded at $475.42, down $0.33, or 0.07% since the insider transaction. Historical insider transactions for Alleghany go as follows:

  • 4-Week # shares bought: 400
  • 4-Week # shares sold: 250
  • 12-Week # shares bought: 400
  • 12-Week # shares sold: 250
  • 24-Week # shares bought: 400
  • 24-Week # shares sold: 250

The average volume for Alleghany has been 69,600 shares per day over the past 30 days. Alleghany has a market cap of $7.6 billion and is part of the financial sector and insurance industry. Shares are up 3.24% year-to-date as of the close of trading on Friday.

Alleghany Corporation, together with its subsidiaries, provides various insurance services in the United States. The company operates in two segments, Reinsurance and Insurance. The company has a P/E ratio of 12.8. Currently, there are no analysts who rate Alleghany a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on Y - FREE

TheStreet Quant Ratings rates Alleghany as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Alleghany Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ZIOPHARM Oncology (ZIOP) - FREE Research Report

Brennan Murray, who is Director at ZIOPHARM Oncology, sold 40,000 shares at $9.70 on June 5, 2015. Following this transaction, the Director owned 12,500 shares meaning that the stake was reduced by 76.19% with the 40,000-share transaction.

The shares most recently traded at $9.35, down $0.35, or 3.69% since the insider transaction.

The average volume for ZIOPHARM Oncology has been 4.6 million shares per day over the past 30 days. ZIOPHARM Oncology has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 84.22% year-to-date as of the close of trading on Friday.

ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Currently, there are 2 analysts who rate ZIOPHARM Oncology a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ZIOP - FREE

TheStreet Quant Ratings rates ZIOPHARM Oncology as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share. Get the full ZIOPHARM Oncology Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Falls Sharply as Wall Street Weighs Trump's New Trade Threats

Dow Falls Sharply as Wall Street Weighs Trump's New Trade Threats

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Intel Gets a Downgrade Following CEO Resignation

Intel Gets a Downgrade Following CEO Resignation

Jim Cramer: Reports of Attempted Trade Truce With China Are False

Jim Cramer: Reports of Attempted Trade Truce With China Are False

Ford and General Motors 'Notably Vulnerable' to Trade War: Moody's

Ford and General Motors 'Notably Vulnerable' to Trade War: Moody's